A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-24. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Habib Thiam - former president of the National assembly, former prime minister, Senegal. Habib Sy - former Minister of Agriculture, Senegal. Iba Der Thiam - Writer, Historian, former Minister of Education. Ibrahima Diallo (politician) – politician who served in the French Senate from 1956 to 1958 Dior Fall Sow - Senegalese jurist and legal scholar, First female prosecutor in Senegal. Khalifa Sall - former mayor of Dakar. Khadidiatou Diallo- Activist, Senegal Mata Sy Diallo - former vice president of the National Assembly. Maba Diakhou Ba – Religious leader, Nioro Senegal Mamadou Dia – Member of French Senate from 1948 to 1956 and the French National Assembly from 1956 to 1958. First Prime Minister of Senegal (1957–62), Senegal Mamadou Moustapha Ba - former Minister of Economy and Finance. Moussa Balde - Former Minister of National Education, Higher Education, Research and Innovation (MENESRI), Senegal. Yérim Habib Sow - Ivorian-Senegalese Entrepreneur, Founder Teyliom Group. Omar Sy – French actor and comedian Ousmane Sow – sculptor, Senegal Oumar Khassimou Dia - Former Minister of planning and Foreign affairs, senegal. Elhadj As Sy - former secretary general of International Federation of Red Cross and Red Crescent Societies. Fodé Seck - Senegalese Diplomat, former president of the UN Security Council. General Mountaga Diallo- former Force Commander of MONUC, former diplomat, Senegal Safiatou Thiam - former Minister of Health. Samba Ndiobène Ka - Former Minister of Agriculture, Rural Equipment and Food Sovereignty.
=== Direct-to-consumer === Direct-to-consumer tests are regulated as medical devices, although they are not necessarily reviewed by the FDA. 23andMe direct-to-consumer genetic tests were originally offered as LDTs, but the FDA challenged that and forced the company to submit the test for approval as a class II medical device.
=== Generic names === The English and generic name of CPA is cyproterone acetate and this is its USANTooltip United States Adopted Name, BANTooltip British Approved Name, and JANTooltip Japanese Accepted Name. The English and generic name of unacetylated cyproterone is cyproterone and this is its INNTooltip International Nonproprietary Name and BANTooltip British Approved Name, while cyprotérone is the DCFTooltip Dénomination Commune Française and French name and ciproterone is the DCITTooltip Denominazione Comune Italiana and Italian name. The name of unesterified cyproterone in Latin is cyproteronum, in German is cyproteron, and in Spanish is ciproterona. These names of cyproterone correspond for CPA to acétate de cyprotérone in French, acetato de ciproterona in Spanish, ciproterone acetato in Italian, cyproteronacetat in German, siproteron asetat in Turkish, and cyproteronacetaat in Dutch. CPA is also known by the developmental code names SH-80714 and SH-714, while unacetylated cyproterone is known by the developmental code names SH-80881 and SH-881.
Sources: en.wikipedia.org
The Earl S. Richardson Library's is the main academic information resource center on the campus. Constructed in 2008, the building covers approximately 222,517 square feet. The library's holding constitutes over 500,000 volumes, and access to over 1 million e-books and 5,000 periodical titles. There are 167 online databases that are subscribed to the Library. Reading and studying spaces are provided with wired and wireless access to databases for research. One such collection in the volumes includes books on Africa, with an emphasis on sub-Saharan Africa. The African-American collection includes papers and memorabilia of such persons as Emmett Jay Scott, secretary to Booker T. Washington. The Forbush Collection is composed of materials associated with the Quakers and slavery. The Martin D. Jenkins Collection was acquired in 1980.
Self-assembling peptides are a category of peptides which undergo spontaneous assembly into ordered nanostructures. Originally described in 1993, these designer peptides have attracted interest in the field of nanotechnology for their potential for application in areas such as biomedical nanotechnology, tissue cell culturing, molecular electronics, and more. Effectively self-assembling peptides act as building blocks for various material and device applications. The essence of this technology is to replicate what nature does: to use molecular recognition processes to form ordered assemblies of building blocks capable of conducting biochemical activities.
== Further reading == Rätsch C (2005) [German edition: 1998]. The Encyclopedia of Psychoactive Plants, Enthnopharmacology and Its Applications. Translated by John R. Baker, with assistance from Annabel Lee and Cornelia Ballent. Rochester, Vermont: Park Street Press. ISBN 978-0-89281-978-2. OCLC 57007969.
Sources: en.wikipedia.org
The primitive gut is suspended from the posterior abdominal wall by the dorsal mesentery. The gastrointestinal tract and associated dorsal mesentery are subdivided into foregut, midgut, and hindgut regions based on the respective blood supply. The foregut is supplied by the celiac trunk, the midgut is supplied by the superior mesenteric artery (SMA), and the hindgut is supplied by the inferior mesenteric artery (IMA). This division is established by the fourth week of development. After this, the midgut undergoes a period of rapid elongation, forcing it to herniate through the navel. During herniation, the midgut rotates 90° anti-clockwise around the axis of the SMA and forms the midgut loop. The cranial portion of the loop moves to the right and the caudal portion of the loop moves toward the left. This rotation occurs at about the eighth week of development. The cranial portion of the loop will develop into the jejunum and most of the ileum, while the caudal part of the loop eventually forms the terminal portion of the ileum, the ascending colon and the initial two-thirds of the transverse colon. As the foetus grows larger, the mid-gut loop is drawn back through the umbilicus and undergoes a further 180° rotation, completing a total of 270° rotation. At this point, about 10 weeks, the caecum lies close to the liver. From here it moves in a cranial to caudal direction to eventually lie in the lower right portion of the abdominal cavity.
== Growth and morphology == In nature, P. digitatum adopts a filamentous vegetative growth form, producing narrow, septate hyphae. The hyphal cells are haploid, although individual hyphal compartments may contain many genetically identical nuclei. During the reproductive stages of its life cycle, P. digitatum reproduces asexually via the production of asexual spores or conidia. Conidia are borne on a stalk called a conidiophore that can emerge either from a piece of aerial hyphae, or from a soil-embedded network of hyphae. The conidiophore is usually an asymmetrical, delicate structure with smooth, thin walls. Sizes can range from 70–150 μm in length. During development, the conidiophore can branch into three rami to produce a terverticillate structure, although biverticillate and other irregular structures are often observed. At the end of each rami, another set of branches called metulae are found. The number of metulae varies from 15–30, with their sizes ranging from 4–6 μm. At the distal end of each metula, conidium-bearing structures called phialides form. Phialides can range in shape from flask-shaped to cylindrical, and can be 10–20 μm long. The conidia produced, in turn, are smooth, with a shape that can range from spherical to cylindrical, although an oval shape is frequently seen. They are 6–15 μm long and are produced in chains, with the youngest at the base of each chain. Each conidium is haploid and bears only one nucleus. Sexual reproduction in P. digitatum has not been observed. Penicillium digitatum can also grow on a variety of laboratory media.
This was intended to demonstrate Rhodesia's continued loyalty to the Queen, but the use of the unmistakably British song at Rhodesian state occasions soon seemed "fairly ironic", as The Times put it. Salisbury started looking for a replacement anthem around the same time as its introduction of the new flag, and in 1974, after four years without an anthem ("God Save the Queen" was formally dropped in 1970), republican Rhodesia adopted "Rise, O Voices of Rhodesia", an anthem coupling original lyrics with the tune of Beethoven's "Ode to Joy". The country's head of state under the republican constitution was the President of Rhodesia, the first of whom was Dupont. State press censorship, which had been introduced on UDI, was lifted in early April 1968. Decimalisation occurred on 17 February 1970, two weeks before Rhodesia's reconstitution as a republic, with the new Rhodesian dollar replacing the pound at a rate of two dollars to each pound. Following the republic's formal declaration the next month, the Rhodesian military removed nomenclatural and symbolic references to the Crown—the Royal Rhodesian Air Force and Royal Rhodesia Regiment dropped their "Royal" prefixes after the Queen formally revoked them because of the declaration, new branch and regimental flags were designed, and the St Edward's Crown surmounting many regimental emblems was expunged in favour of the "Lion and Tusk", a motif from the coat of arms of the British South Africa Company that had been used in Rhodesian military symbolism since the 1890s.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.